- Home
- DBD vs WGS Comparison
DBD vs WGS Comparison
Compare DBD & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- WGS
- Stock Information
- Founded
- DBD 1859
- WGS 2017
- Country
- DBD United States
- WGS United States
- Employees
- DBD N/A
- WGS N/A
- Industry
- DBD EDP Services
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- DBD Technology
- WGS Technology
- Exchange
- DBD Nasdaq
- WGS Nasdaq
- Market Cap
- DBD 1.8B
- WGS 1.5B
- IPO Year
- DBD N/A
- WGS N/A
- Fundamental
- Price
- DBD $40.27
- WGS $68.43
- Analyst Decision
- DBD Strong Buy
- WGS Strong Buy
- Analyst Count
- DBD 2
- WGS 5
- Target Price
- DBD $57.50
- WGS $67.00
- AVG Volume (30 Days)
- DBD 255.4K
- WGS 753.8K
- Earning Date
- DBD 11-07-2024
- WGS 10-29-2024
- Dividend Yield
- DBD N/A
- WGS N/A
- EPS Growth
- DBD N/A
- WGS N/A
- EPS
- DBD 0.00
- WGS N/A
- Revenue
- DBD $3,799,000,000.00
- WGS $267,228,000.00
- Revenue This Year
- DBD $0.86
- WGS $43.70
- Revenue Next Year
- DBD $1.19
- WGS $16.78
- P/E Ratio
- DBD $7,622.28
- WGS N/A
- Revenue Growth
- DBD 2.88
- WGS 29.41
- 52 Week Low
- DBD $22.74
- WGS $1.29
- 52 Week High
- DBD $51.81
- WGS $89.11
- Technical
- Relative Strength Index (RSI)
- DBD 34.53
- WGS 51.05
- Support Level
- DBD $38.50
- WGS $71.45
- Resistance Level
- DBD $42.00
- WGS $82.18
- Average True Range (ATR)
- DBD 2.10
- WGS 7.58
- MACD
- DBD -0.94
- WGS -1.36
- Stochastic Oscillator
- DBD 8.72
- WGS 17.21
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are banking which offers integrated solutions for financial institutions and retail which offers solutions, software, and services which improve the checkout process for retailers.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.